Quick Shot #5 Answer
Answer: A and D (infliximab and tofacitinib)
Both anti-TNF agents (infliximab) and tofacitinib have shown efficacy for ulcerative colitis AND spondyloarthropathy such as ankylosing spondylitis.
- Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015 Jun;74(6):1241-8. doi: 10.1136/annrheumdis-2014-205322. Epub 2014 Apr 9. PMID: 24718959.
- Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, Wang L, Wu J, Menon S, Wang C, Dina O, Fallon L, Kanik KS, van der Heijde D. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021 Apr 27;80(8):1004–13. doi: 10.1136/annrheumdis-2020-219601. Epub ahead of print. PMID: 33906853; PMCID: PMC8292568.